<!DOCTYPE html><html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"><meta name="format-detection" content="telephone=no"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no"><link rel="stylesheet" href="css/main.min.css"><script src="js/all.min.js"></script><script type="text/javascript">var slideNumber = 7</script></head><body class="s7"><div class="content-wrap"><nav><div onclick="iRep.go(1)" class="home-button"></div><ul><li onclick="iRep.go(3)" class="real-world-evidence"><span>REAL WORLD</span></li><li onclick="iRep.go(4)" class="evidence active"><span>EVIDENCE</span></li><li onclick="iRep.go(12)" class="reversal"><span>REVERSAL</span></li><li onclick="iRep.go(14)" class="take-action"><span>COST</span></li><li onclick="iRep.goToolbox()" class="toolbox"><span>TOOLBOX</span></li><li onclick="iRep.go(16)" class="pi"><span>PI</span></li></ul></nav><div class="page-nav"><div onclick="iRep.go(12)" class="page-next"></div><div onclick="iRep.prevSlide()" class="page-prev"></div></div><article><div class="panel1"><h3>Apixaban 2.5mg b.d.: bleeding outcomes<sup>1</sup></h3><div class="labels"><div onclick="iRep.go(6)" class="label"><div class="text">PRADAXA<sup>®</sup> 110mg</div></div><div class="label next-panel"><div class="text">APIXABAN <br/>2.5 & 5mg</div></div><div onclick="iRep.go(8)" class="label"><div class="text">RIVAROXABAN <br/> 15mg</div></div></div><div class="down-bar"></div><div class="graph"><div class="chart"><div class="title">Apixaban 2.5mg b.d.<sup>1</sup></div><div class="bars"><span>INTRA-CRANIAL</span><div class="bar bar1"><div class="text">NO DATA</div></div></div><div class="bars"><span>MAJOR</span><div class="bar bar2"><div class="text">3.40% ARR<br/>51% RRR<br/></div></div></div><div class="bars"><span>MAJOR GI</span><div class="bar last bar3"><div class="text">NO DATA</div></div></div></div><div class="chart2"><div class="title">Pradaxa<sup>®</sup> 110mg b.d.<sup>2–4</sup></div><div class="bars"><span>INTRA-CRANIAL</span><div class="bar bar1"><div class="text">0.53% ARR<br/>70% RRR<br/><span>(p<0.001)</span></div></div></div><div class="bars"><span>MAJOR</span><div class="bar bar2"><div class="text">0.69% ARR<br/>20% RRR<br/><span>(p=0.003)</span></div></div></div><div class="bars"><span>MAJOR GI</span><div class="bar last bar3"><div class="text">0.08% ARI<br/>8% RRI<br/><span>(p=ns)</span></div></div></div></div><div class="over-bar"><p>W</p></div><div class="left"></div><div class="note">Please note that these data are not from a head-to-head trial</div></div></div><div class="panel2 hide"><h3>Apixaban 2.5 and 5mg b.d.: bleeding outcomes<sup>1</sup></h3><div class="labels"><div onclick="iRep.go(6)" class="label"><div class="text">PRADAXA<sup>®</sup> 110mg</div></div><div class="label prev-panel"><div class="text">APIXABAN <br/>2.5mg</div></div><div onclick="iRep.go(8)" class="label"><div class="text">RIVAROXABAN <br/> 15mg</div></div></div><div class="down-bar"></div><div class="graph"><div class="chart"><div class="title"></div><div class="bars"><span>INTRA-CRANIAL</span><div class="bar bar1"><div class="text">0.47% ARR<br/>58% RRR<br/><span>(p<0.001)</span></div></div></div><div class="bars"><span>MAJOR</span><div class="bar bar2"><div class="text">0.96% ARR<br/>31% RRR<br/><span>(p<0.001)</span></div></div></div><div class="bars"><span>MAJOR GI</span><div class="bar last bar3"><div class="text">0.10% ARR<br/>11% RRR<br/><span>(p=ns)</span></div></div></div></div><div class="over-bar"><p>W</p></div><div class="left"></div></div></div></article><div class="overlay"></div><div class="sidebar"><ul><li class="brain-tab tab"></li><li class="warfarin-tab tab"></li><li class="references-tab tab"></li></ul><div class="panel"><div class="close-button"></div><div class="content references"><div class="text"><b>References: 1.</b> Granger CB,<em> et al. N Engl J Med</em> 2011; 365:981–92.<b> 2.</b> Connolly SJ,<em> et al. N Engl J Med</em> 2009; 361:1139–51.<b> 3.</b> Connolly SJ,<em> et al. N Engl J Med</em> 2010; <br/> 363:1875–6.<b> 4.</b> Connolly SJ,<em> et al. N Engl J Med</em> 2014; 371:1464–5.<b> 5.</b> Boehringer Ingelheim. Pradaxa<sup>®</sup> 110mg hard capsules Summary of Product Characteristics. </br><b> 6.</b> Bristol-Myers Squibb-Pfizer. Eliquis 2.5mg film coated tablets Summary of Product characteristics.</div></div><div class="content warfarin"><img src="img/s07/popup.png"></div><div class="content brain"><h3 class="title-popup">Apixaban 2.5mg b.d.: stroke outcomes<sup>1</sup></h3><div class="down-bar"></div><div class="graph"><div class="chart"><div class="title-graph">Apixaban 2.5mg b.d.<sup>1</sup></div><div class="bars"><div class="title1">ISCHAEMIC</div><div class="bar bar1"><div class="text">NO DATA</div></div></div><div class="bars"><div class="title1">HAEMORR-<br/>HAGIC</div><div class="bar bar2"><div class="text">NO DATA</div></div></div><div class="bars"><div class="title1">STROKE/</br>SYSTEMIC<br/>EMBOLISM</div><div class="bar bar3"><div class="text">1.60% ARR<br/>48% RRR</div></div></div></div><div class="chart2"><div class="title-graph">Pradaxa<sup>®</sup> 110mg b.d.<sup>2-5</sup></div><div class="bars"><div class="title1">ISCHAEMIC</div><div class="bar bar1"><div class="text">0.14% ARI<br/>13% RRI<br/><span>(p=ns)</span></div></div></div><div class="bars"><div class="title1">HAEMORR-<br/>HAGIC</div><div class="bar bar2"><div class="text">0.26% ARR<br/>69% RRR<br/><span>(p<0.001)</span></div></div></div><div class="bars"><div class="title1">STROKE/</br>SYSTEMIC<br/>EMBOLISM</div><div class="bar bar3"><div class="text">0.18% ARR<br/>11% RRR<br/><span>(p=ns)</span></div></div></div></div><div class="over-bar"><p>W</p></div><div class="left"></div><div class="note">Please note that these data are not from a head-to-head trial</div></div></div></div></div></div></body></html>